Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells
نویسندگان
چکیده
منابع مشابه
itor Drug Resistance in Chronic Myelogenous Leukemia
ownload pite the initial effectiveness of oncogene-directed cancer therapeutics, acquired drug resistance rethe ultimate “Achilles' heel” for long-term durable remission in cancer patients. Acquisition of drug nce is not more evident elsewhere than in the use of tyrosine kinase inhibitors, imatinib and da, for patients with chronic myelogenous leukemia. Hence, even though imatinib initially pro...
متن کاملStrategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia.
Imatinib mesylate was approved for the treatment of chronic myelogenous leukemia more than 5 years ago. This drug enabled us to put a very high percentage of patients into hematologic, cytogenetic, and molecular remission. Some patients were resistant to Imatinib from the onset of the treatment whereas others became resistant after showing an initial response to Imatinib mesylate. Various strat...
متن کاملImatinib Therapy in Chronic Myelogenous Leukemia
Chronic myelogenous leukemia (CML) is a clonal proliferative disease originating from a pluripotential stem cell in which a 9:22 translocation, Philadelphia (Ph) chromosome, results in the production of BCR-ABL fusion protein that has constitutive tyrosine kinase activity and deregulates signal transduction pathways, thus causing leukemia. The natural course of CML is usually triphasic (chronic...
متن کاملimatinib therapy in chronic myelogenous leukemia and thyroid function tests.
introduction: imatinib, a tyrosine kinase inhibitor which resulted in much improvement in the treatment of chronic myelogenous leukemia (cml), may adversely affect thyroid gland function. to date, assessment of thyroid function during imatinib therapy has limited to retrospective studies. the aim of this study was to evaluate the effects of imatinib on thyroid function in a prospective manner. ...
متن کاملCharacteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
PURPOSE Although dual src-family kinase/BCR/ABL inhibitor, dasatinib (BMS-354825), provides therapeutic advantages to imatinib-resistant cells, the mechanism of dasatinib resistance was not fully known. EXPERIMENTAL DESIGN We used TF-1 BCR/ABL cells, by introducing the BCR/ABL gene into a leukemia cell line, TF-1 and K562, and established dasatinib- (BMS-R) and imatinib-resistant (IM-R) cells...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Medical Science
سال: 2021
ISSN: ['2657-7941']
DOI: https://doi.org/10.5114/aoms.2020.101042